Cancer Network Staff

Final COMBI-I data show a survival advantage with spartalizumab plus dabrafenib/trametinib over dabrafenib/trametinib alone in BRAF V600-mutant melanoma.

Savolitinib/osimertinib significantly improved progression-free survival vs osimertinib alone as first-line treatment in the phase 3 SANOVO trial.

BioNTech has terminated a phase 2 trial of autogene cevumeran in ctDNA-positive, resected colorectal cancer after a DSMB found an overall survival imbalance.

ASCO’s first living guideline for recurrent ovarian cancer recommends platinum-based doublets, selective bevacizumab, and mirvetuximab soravtansine for FRα-positive platinum-resistant disease.

The FDA granted fast track designation to the ADC SOT106 for soft tissue sarcoma, with a first-in-human trial planned this year.

Paxalisib produced a 100% clinical benefit rate and an 83% objective response rate in patients with metastatic triple-negative breast cancer.

ASCO has issued a critical drug supply warning as some practices report just weeks of ifosfamide inventory remaining, with no direct substitute available.

Enrollment for a phase 1 trial evaluating ADI-212, an armored allogeneic gamma delta 1 CAR T cell therapy, in metastatic CRPC is planned for Q4 2026.

Neoadjuvant botensilimab plus balstilimab produced major pathologic responses in 41% of pMMR and 100% of dMMR colorectal tumors in the phase 2 NEST trial.

New CNS metastasis data link gabapentin to fewer brain mets, spotlight trial barriers, and show promise for intrathecal therapy and osimertinib.

In the final analysis of the phase 3 MAIA trial, daratumumab-based treatment yielded a median overall survival of 90.3 months in transplant-ineligible NDMM.

Final phase 1/1b data for soquelitinib in T-cell lymphoma showed a 37.5% ORR and a 28.1-month median OS in patients who received 1 to 3 prior lines of therapy.

The regulatory submission to expand the gedatolisib label to HR+/HER2-, PIK3CA-mutant advanced breast cancer is based on positive VIKTORIA-1 trial data.

Josef Vymazal, MD, DSc, discusses a prospective study comparing delayed single- and double-dose gadopiclenol MRI for detecting small brain metastases.

The FDA has approved daraxonrasib for patients with previously treated metastatic pancreatic ductal adenocarcinoma based on RASolute 302 trial data.

In a real-world setting, venetoclax plus a hypomethylating agent produced a median overall survival of 13.0 months in newly diagnosed acute myeloid leukemia.

The FDA granted fast track designation to the pan-RAS molecular glue ERAS-0015 for metastatic pancreatic adenocarcinoma.

In a real-world setting, enfortumab vedotin plus pembrolizumab produced a 50.2% ORR among patients with metastatic/locally advanced urothelial carcinoma.

The FDA has approved zanidatamab plus chemotherapy for the first-line treatment of HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma.

Japan’s MHLW approved sevabertinib for HER2-mutant advanced or recurrent NSCLC across all lines of therapy based on phase 1/2 SOHO-01 data.

Lizza Hendriks, MD, PhD, discusses clinical trial designs, multidisciplinary care, and promising research at the 2026 SNO ASCO CNS Metastases Conference.

In a SEER-based cohort of more than 20,000 adults, 5-year Hodgkin lymphoma survivors had nearly double the all-cause mortality of the general population.

The European Commission based its approval of teclistamab plus daratumumab for relapsed/refractory multiple myeloma on data from the MajesTEC-3 study.

The FDA accepted a priority review application for dostarlimab in untreated dMMR/MSI-H locally advanced rectal cancer, backed by AZUR-1 trial data.

The next major problem to tackle for SRS in brain metastases management is how to handle necrosis rates, according to Ayal Aizer, MD, MHS.

Patients in US counties with the highest medical debt burden had higher odds of stage IV cancer diagnosis and worse survival than those in the lowest-burden counties.

The FDA cited outstanding manufacturing observations while raising no concerns about clinical data, bioequivalence, or stability in its CRL.

The FDA granted fast track designation to safusidenib for IDH1-mutant glioma, building on updated phase 2 data and a broadening clinical development program.

Phase 3 LITESPARK-011 results show belzutifan/lenvatinib significantly improved PFS and ORR vs cabozantinib in previously treated advanced ccRCC.

[68Ga] Ga-NYM096 is the first China-originated radiopharmaceutical to receive FDA breakthrough therapy designation for ccRCC.